ARTICLE | Clinical News
PQ912: Phase IIa started
March 23, 2015 7:00 AM UTC
Probiodrug began the double-blind, placebo-controlled, European Phase IIa SAPHIR trial to evaluate 800 mg oral PQ912 twice daily for 3 months in about 110 patients with early stage AD. ...